RxDoctor Payments Data

Faisal Rafiq, MD

Psychiatry · Amityville, NYNPI 1770734238

Payments from drug & device makers

$110,879in general payments, 2019–2025

Across 1,749 payments — averaging $63.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$51K
  • Teva Pharmaceuticals USA, Inc.$24K
  • Alkermes, Inc.$10K
  • Otsuka America Pharmaceutical, Inc.$4K
  • Lundbeck LLC$4K
  • AbbVie$2K
  • plus $16K from 31 others

What the payments were for

  • Consulting fees$47,23843%
  • Speaking & faculty fees$27,80025%
  • Travel & lodging$2,1372%
  • Food & beverage$33,52730%
  • Education$1770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,879 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$263,105
Medicare patients
89
Services billed
1,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$127,815
RexultiBrexpiprazole44$101,556
VraylarCariprazine Hcl26$39,417
SunosiSolriamfetol Hcl20$17,296
AuvelityDextromethorphan Hbr/Bupropion16$17,193
SpravatoEsketamine Hcl12$16,766
OzempicSemaglutide12$11,619
Aripiprazole62$9,047
VyvanseLisdexamfetamine Dimesylate18$6,883
Loreev XrLorazepam15$6,632
Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl17$4,479
Quetiapine Fumarate126$3,998
Gabapentin93$3,478
Fluvoxamine Maleate ErFluvoxamine Maleate12$3,133
Lurasidone Hcl13$2,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$24,442$127,81511 claims
Otsuka America Pharmaceutical, Inc.Rexulti$4,281$101,55644 claims
AbbVieVraylar$2,426$39,41726 claims
Axsome Therapeutics, Inc.Sunosi, Auvelity$50,737$34,48936 claims
Johnson & JohnsonSpravato$1,393$16,76612 claims
Novo NordiskOzempic$314$11,61912 claims
Almatica Pharma LLCLoreev Xr, Sertraline Hcl$461$7,00375 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$1,599$6,88318 claims
Lilly USA, LLCOlanzapine$48$92581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →